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Abstract
Background: The high false negative rates for initial prostate biopsies refer a large number of the men for repeat
biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically
benign biopsies could provide a tool to discriminate the patients who need repeat biopsy or intensive follow-up
from those who do not. Here we examined the diagnostic applicability of alpha-methylacyl CoA racemase (AMACR)
and androgen receptor (AR) mRNA expression and AMACR protein levels in benign and cancerous prostatic tissue.
Methods: AMACR and AR mRNA levels were measured with quantitative, reverse-transcription PCR (qRT-PCR) assays
in 79 radical prostatectomy (RP) cases (including 69 benign (RP-Be) and 69 cancerous (RP-PCa) samples) and
19 benign prostate samples obtained from cystoprostatectomies. To further determine the detailed areas of
altered AMACR expression, AMACR mRNA level measurement and protein staining were performed for three
cross-sectioned RP cases.
Results: The median AMACR and AR expression levels were 194.6 (p < 0.0001) and 6.6 (p = 0.0004) times higher in
RP-PCa samples than in the benign cystoprostatectomy (CP) samples, respectively. There was no statistically significant
difference between RP-PCa and RP-Be samples, except for AMACR/KLK3 (Kallikrein-Related Peptidase 3) ratio, which
was significantly higher in RP-PCa samples than in RP-Be samples (p = 0.016). In the systematic study of cross-sections,
AMACR mRNA was detected in all of the studied areas including histologically benign tissue, but at significantly higher
levels in carcinoma areas (p < 0.001). AMACR protein expression was detected in 80 % (28/35) of the areas
that contained carcinoma and in 37 % (44/119) of the benign and PIN areas from the same patients.
Conclusions: AMACR transcripts were detected in all RP-PCa and RP-Be samples but not in non-cancerous CP
samples, which suggest a global increase of AMACR expression in cancerous prostates. Therefore patients with
false negative biopsies might benefit from an AMACR mRNA measurement when assessing their cancer risk.
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Background
Prostate cancer (PCa) is the most common cancer in
men and the second leading cause of cancer-related
death. The current routine diagnostic approach employs
a combination of digital rectal examination (DRE) and
measurement of serum level of prostate specific antigen
(PSA) followed by histological examination of prostate
biopsies. However, negative biopsy results have been re-
ported for 70–80 % of the men in the United States who
undergo prostate biopsy each year [1]. Considering the
fact that in those men, cancer foci might have been
missed due to sampling error, repeated biopsies for cases
with elevated PSA level are an assuring option. Re-
biopsies or increasing the number of biopsy cores have
been shown to improve the diagnostic accuracy and
reduce false negative results [2], but the procedures are
costly and generate discomfort for patients. Therefore,
biomarkers associated with high risk of presence of
malignancy on histologically benign biopsies could pro-
vide an additional tool in identifying those patients who
would truly benefit from a repeat biopsy or intensive
follow-up.
Extensive research based on high-throughput gene
expression profiling has aimed to identify new bio-
markers in PCa tissues to better address the limitations
of present diagnostic and prognostic approaches. Here
we performed validation of diagnostic capabilities of
quantitative measurement of alpha-methylacyl CoA
racemase (AMACR) and androgen receptor (AR) tran-
scripts by RT-PCR for PCa diagnosis.
AMACR enzyme is involved in peroxisomal beta-
oxidation of branched-chain fatty acids and their deriva-
tives [3]. In PCa AMACR is highly expressed at both
mRNA and protein levels [4]. However, AMACR is also
frequently expressed in prostatic intraepithelial neoplasia
(PIN) [5] and variable expression may be found in be-
nign prostatic glandular epithelium across all age groups
[6]. Therefore, to resolve diagnostic challenges in clinical
pathology AMACR staining is typically combined with a
basal epithelial cell marker such as p63 or 34βE12 that
are not present in PCa.
The growth and maintenance of prostate tissue is
dependent on androgens produced in testes and adrenal
glands [7] and the intracellular androgen receptor (AR)
signaling plays a key role in the formation and develop-
ment of PCa. Androgen-ablation therapy is one of the
most common and successful treatments of PCa but
with time the tumor frequently reaches an androgen-
independent state. One mechanism for PCa to become
castration resistant is due to the amplification and over-
expression of AR gene enabling the cancer cells to grow
with very low levels of androgen [8, 9]. Thus, overex-
pression of AR promotes the formation and progression
of PCa as well as castration resistant PCa.
Overexpression of AMACR - at both mRNA and pro-
tein levels - has been reported in cancerous prostatic tis-
sue when compared to benign prostatic hyperplasia
(BPH) and normal prostate tissue [4, 10–14]. The aim of
our study was to investigate the potential use of AMACR
and AR mRNA expression levels to improve detection of
PCa. We examined the mRNA levels of AMACR and AR
in 157 prostate tissues by using internally standardized,
truly quantitative reverse-transcription PCR (qRT-PCR)
assays. The samples were collected from 79 cases of rad-
ical prostatectomies (RP) rapidly after the procedure
both from the suspected tumor sites and from areas
away from the tumor site. Cystoprostatectomy derived
samples (CP) from 19 non-PCa patients or patients har-
boring incidental PCa were used as controls. All cysto-
prostatectomies were performed because of bladder
cancer with no clinical suspicion of PCa. Based on the
initial, AMACR-related findings of these experiments,
we also set out to perform a preliminary, systematic
evaluation of whole prostate cross-sections from three
PCa patients to determine if samples from areas outside
the pathologically determined tumor lesions could be
equally informative of the presence of cancer. AMACR
expression in these cross-sections was examined on both
mRNA and protein levels by qRT-PCR and immunohis-
tochemistry, respectively, and compared to the tissue
morphology.
Methods
Radical prostatectomy and cystoprostatectomy samples
The study protocol was approved by the Ethics Commit-
tee of the Hospital District of Southwest Finland and it
was in accordance with the Helsinki Declaration of
1975, as revised in 1996, with written informed consent
obtained from each participant.
In total, 157 prostate tissue samples were examined.
The cohort consisted 79 RP patients (Table 1) from
Table 1 Patients characteristics
Number of patients 79
Age at surgery (years) Average (min,max) 61.5 (48, 71)
Preoperative serum PSA Average (min,max) 8.4 (1.4, 30)
Pathological T-category Number of samples
(percentage)
pT2 33 (42 %)
pT3 and pT4 41 (52 %)
Unknown 5 (6 %)
Pathological Gleason score
≤6 45 (57 %)
7 18 (23 %)
≥8 12 (15 %)
Unknown 4 (5 %)
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whom 138 tissue samples containing 69 histologically
benign samples (RP-Be) and 69 cancerous samples (RP-
PCa) were obtained after radical prostatectomies in
Turku University Hospital in Turku, Finland for clinic-
ally localized PCa. (Table 2 represents clinicopathologi-
cal data for 138 samples obtained from 79 radical
prostatectomy specimens). Two tissue samples were col-
lected from each prostate: one from an area suspected to
contain cancer and one from a macroscopically normal
area as a control [15]. Pathological examination revealed
that for some patients both samples had been taken
from either benign or cancerous areas. For 59 prostates
we examined both samples (for 30/59 prostates one of
the samples had been taken from a benign area and the
other from a cancerous area; for 15/59 both samples
were from a cancerous area; and for 14/59 both samples
were from a benign area), and for 9 and 11 prostates, we
only had access to one sample per prostate, similarly
taken either from the cancerous or control area, respect-
ively. The samples were collected immediately after the
removal of the organ and stored in quanidine isothio-
cyanate buffer [15]. The final content of the samples
(benign or cancerous) was determined from hematoxylin-
eosin (HE) stained frozen sections obtained next to the
fresh frozen tissue samples.
Additionally, 19 histologically benign prostatic tissue
samples were obtained from patients who underwent
cystoprostatectomy due to bladder cancer without clin-
ical evidence of PCa in Skåne University Hospital in
Malmö, Sweden. At the time of histological evaluation,
seven cases showed no evidence of PCa (CP-Be) while
12 had incidental PCa (CP-PCa)).
Prostate cross-section samples
Single whole prostate cross-sections were obtained from
three patients with localized PCa who underwent RP in
Turku University Hospital in Turku, Finland. The cohort
and sample collection has been previously reported [16].
Briefly, a 2 mm horizontal mid-plane tissue slice
covering the entire gland was obtained from each pros-
tate for the experiment. To be able to have a unique
coordinate code for each piece of tissue, the prostate
slice was fixed on a Styrofoam plate with a 5 × 5 mm
grid guide on it. To avoid cross-contamination, sterile
blades were used to cut the prostate slices further into
5 × 5 × 2 mm pieces. Based on the size of the prostate
gland, 48, 62 and 44 pieces of tissue were obtained from-
prostates A, B and C, respectively. The samples were
stored in RNAlater (Qiagen) at −20 °C until RNA
extraction.
For histological examination, from each specimen, the
tissue adjacent to the slice used for mRNA measure-
ments were fixed in formalin and embedded in macro
paraffin blocks (FFPE). The FFPE blocks covering the
superior and inferior side of the cross-section were cut
to 5 μm sections and HE-stained.
RNA isolation and reverse transcription
Total RNA was extracted from the tissues and reverse
transcribed to cDNA as previously described [15].
During the extraction, a known amount of RNA of artifi-
cially mutated KLK3 gene called mmPSA [17] was added
to samples as internal standard after the cell lysis.
Real-time PCR
A previously described concept utilizing target-specific
oligonucleotide probes and time-resolved fluorometry
were used to detect the accumulation of AMACR and AR
transcripts [18, 19]. Oligonucleotide primers and probes
(Table 3) were purchased from Thermo (Germany). All
samples were run in triplicate in a reaction volume of
25 μl containing 2.5 μl of template cDNA using a previ-
ously described temperature profile [19] and external
DNA standards [15].
Immunohistochemistry
For cross-section studies, histological macrosections of
5 μm in thickness were cut from the FFPE blocks of
each prostate (A,B and C), next to the HE-stained sec-
tions. Paraffin was removed with xylene and the sections
were rehydrated with series of alcohol. Antigen retrieval
was carried out by microwaving the slides in Target
Retrieval solution (Dako) at pH 9 for 7 min. The tissue
sections were incubated for one hour with rabbit mono-
clonal AMACR (P504S) antibody (1:200, clone 13H4,
Zeta Corporation). The primary antibody was detected
with EnVision + Dual Link System-HRP (Dako) and visu-
alized with DAB+ chromogen solution (Dako). The
slides were observed by an experienced uropathologist
using a Leica DM3000 light microscope equipped with
Leica DFC 420 digital camera and Leica Application
Suite version 2.5.0 R1 (Leica Microsystems, Wetzlar).
Table 2 Clinicopathological data for 138 samples obtained from
79 radical prostatectomy specimens
Number of samples (percentage)
Pathological T-category
pT2 57 (41 %)
pT3 and pT4 72 (52 %)
Unknown 9 (7 %)
Pathological Gleason score
≤ 6 81 (58 %)
7 27 (20 %)
≥ 8 22 (16 %)
Unknown 8 (6 %)
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Data analysis
The obtained mRNA levels were normalized to total
RNA amount and the previously determined internal
RNA standard levels. Samples were considered as posi-
tive only when all three replicates were positive and
above the lowest detection limit of the assay. To calcu-
late the expression levels of AMACR or AR in relation to
KLK3 (the gene encoding PSA), the mRNA copy num-
bers were divided by previously determined KLK3
mRNA levels [20].
Linear regression models were created to test whether
the type of sample (RP-BE, RP-PCa, CP-Be, CP-PCa)
was associated with the log-transformed expression
levels of AR, AMACR, KLK3, AR/KLK3 or AMACR/
KLK3. Mann–Whitney U test was used to evaluate
whether there were statistically significant differences in
the gene expression levels between any two of the
groups. A significance level of p = 0.05 was used.
For the systematic study of cross-sections, the histology
of tissue samples used for mRNA expression measure-
ments was defined by dividing the digital images of HE-
stained tissue slides into equal amount of regions with the
cross-sections used in mRNA experiments. Each sample
piece was given coordinates on two axes (one axis got
values from A to K and the other axis from 1 to 10). Based
on histopathological examination, the samples were cate-
gorized into three groups: carcinoma (n = 35), if one or
both adjacent HE-stained sections revealed adenocarcin-
oma at that location; histologically benign tissue (n =
112), if that is what both HE-stained sections con-
tained; and PIN (n = 7), if one or both HE-stained
sections contained PIN lesions but no carcinoma.
Results
AMACR, AR and KLK3 mRNA expression in RP and CP
samples
For the PCa patients, the median, minimum and max-
imum age and preoperative PSA level in serum were 63
(48 and 71) years and 6.95 (1.4 and 30) ng/ml, respect-
ively. Detailed clinicopathological data of the patients
are shown in Table 1.
The limit of detection for the AMACR assay was 10
copies/μl of template DNA and 1 copy/μl of template
DNA for the AR and KLK3 assays. AMACR mRNA was
detected in all RP-Be, RP-PCa and CP-PCa samples but
only in 2 out of 7 CP-Be tissue samples (Fig. 1a). All
tissue samples were found to contain detectable levels of
AR and KLK3 transcripts. Table 4 represents the mRNA
expression level of target genes in different group of
samples.
Compared to the 19 CP samples, the median AMACR
expression level was 126 times higher in the RP-Be sam-
ples (p < 0.0001) and 195 times higher in the RP-PCa
samples (p < 0.0001) (Fig. 1). When the median AMACR
expression level in the RP-PCa samples was compared
to the mean value of the two AMACR positive CP-Be
samples there was a 682-fold difference (p < 0.0001).
There was no statistically significant difference in
AMACR mRNA levels between the RP-PCa and RP-Be
groups. Comparison of AMACR expression level by
paired t-test between cancerous and benign samples for
30 patients who had two matched samples resulted in
insignificant difference (P > 0.05). However, the AMACR
to KLK3 mRNA ratio was 5.3 times higher in the RP-
PCa than in the RP-Be group (p = 0.012).
In comparison to all of the 19 CP samples, the median
level of AR expression was 6.4 times higher in the RP-Be
samples (p < 0.0001) and 6.6 times higher in the RP-PCa
samples (p = 0.0004) (Fig. 1). The greatest difference in
median levels of AR expression was found between the
RP-PCa samples and the CP-Be samples (11.5-fold, p =
0.004). No statistically significant differences were seen
in AR or KLK3 expression, nor in AR/KLK3 mRNA ratio
between the RP-PCa and RP-Be samples.
The mRNA levels of the target genes were not associ-
ated with Gleason grade in the RP samples, but the
Table 3 The oligonucleotides used in this study
Oligonucleotide Sequence (5′ to 3′) Positiona Lanthanide chelate label or
quencher molecule
AMACR forward primer TTGTCAGGTGTTCTCTCAAA 481–500
AMACR reverse primer CTTCCACCATATTTGCATC 637–655
AMACR reporter probe CbTGAATCTCCTGGCTGACTTTGCTGG 535–560 9d-α gal-EuIII
AMACR quencher probe TCAGCCAGGAGATTCAGc 535–551 Dabcyl
AR forward primer GCTGAAGGGAAACAGAAGTAC 328–348
AR reverse primer CTCTCCTTCCTCCTGTAGTTTC 480–501
AR reporter probe TbTGTCGTCTTCGGAAATGTTATGAAGCAGG 408–437 9d-α gal-EuIII
AR quencher probe AACATTTCCGAAGACGACAAc 408–427 Dabcyl
agene bank accession numbers NM_014324 and NM_001011645 were used for AMACR and AR nucleotide sequences, respectively
binternally amino-modified C6-base for labeling with Eu chelate
cquencher molecule
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expression levels of target genes were statistically signifi-
cantly higher in samples from men with either stage pT3
or pT4 tumors (n = 72) than in samples from men
with PCa classified as pT2 (n = 57) (AMACR, p =
0.006; AR, p = 0.005 and KLK3, p = 0.004).
Based on Pearson’s correlation coefficient, there was a
strong correlation (r = 0.86) between AR and AMACR
expression levels when samples from all groups were
combined. Furthermore there was no strong correl-
ation between AMACR or AR and serum PSA (R =
0.46 and R = 0.18, respectively).
The receiver operating characteristic (ROC) curve
analyses for AMACR, AR and KLK3 mRNA expres-
sion for evaluating the diagnostic potency and dis-
crimination power of the target genes between all RP
samples and CP samples produced area under the
curve (AUC) values of 0.94, 0.74 and 0.61, respect-
ively. The ROC curve analyses for AMACR, AR and
KLK3mRNA expression for evaluating the correlation
of the expression level with histology between RP-
PCa and CP samples produced AUC values of 0.923,
0.717 and 0.58, respectively (Fig. 2a). Corresponding
AUC values for RP-Be specimens were 0.89, 0.77 and
0.64, respectively (Fig. 2b).
Systematic analysis of AMACR mRNA and protein
expression in prostate tissue cross-sections
AMACR mRNA was universally expressed in all tissue
pieces covering the whole cross-section of prostates A, B
and C included in the analysis. As a comparison, all
A B
Fig. 1 a KLK3, AR and AMACR mRNA levels in cystoprostatectomy (CP) samples (with and without incidental PCa), histologically benign radical
prostatectomy (RP-Be) samples and cancerous radical prostatectomy (RP-PCa) samples. b AMACR mRNA levels in CP samples without incidental
PCa (CP-Be), CP samples with incidental PCa (CP-PCa), RP-Be and RP-PCa samples. The top whisker represents highest case within 1.5 times IQR.
The top line of the box represents the 3rd quartile, the line in the middle of the box represents the median, the bottom line of the box represents
1st quartile and bottom whisker represents the lowest case within 1.5 times IQR. Open circles represent the outlier values
Table 4 The mRNA expression level (copies/μg of total RNA) of target genes in different group of samples
Expression level (copies/μg of total RNA)
Target genes CP-Be (n = 7) CP-PCa (n = 12) RP-Be (n = 69) RP-PCa (n = 69)
KLK3 1 × 109 (4.6 × 106, 3.2 × 1010) 1.2 × 109(7.8 × 106, 9.9 × 1010) 3.2 × 109(7.8 × 107,2.6 × 1012) 2.1 × 109(9.9 × 107,3.1 × 1013)
AMACR 0 (0, 2.7 × 104) 3.5 × 105(8.1 × 103,4.2 × 106) 7 × 106(6.2 × 102,4.1 × 1010) 8.3 × 106(1 × 103,1.5 × 1010)
AR 5.1 × 104 (7.8 × 103, 1,2 × 106) 1 × 105(4.4 × 104,1.1 × 106) 5.6 × 105(1.7 × 104,6.2 × 107) 5.5 × 105(1 × 104,6.5 × 107)
Data are presented as median (min, max). CP-Be represents cystoprostatectomy samples with no evidence of PCa, CP-PCa represents cystoprostatectomy samples
with incidental PCa, RP-Be represent histologically benign samples from radical prostatectomy specimens and RP-PCa represents cancerous samples from radical
prostatectomy specimens
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measured values from the cross-section samples were
above the highest expression level seen in CP-Be sam-
ples (Fig. 3). There was a significant, 1.9-fold differ-
ence (p < 0.001) in median AMACR mRNA levels
between carcinoma samples (n = 35) and histologically
benign (n = 112) samples. There was no significant
difference between PIN samples (n = 7) and either
carcinoma or histologically benign samples.
In the immunohistochemical analysis (Fig. 4), AMACR
protein was detected in all of the three prostate cross-
Fig. 2 ROC curve analyses for KLK3, AR and AMACR mRNA expression. a ROC curve analysis for RP-PCa and CP tissues. AUC values are 0.58, 0.717
and 0.923 for KLK3, AR and AMACR mRNA levels, respectively. b ROC curve analysis for RP-Be and CP tissues. AUC values are 0.64, 0.77 and 0.89 for
KLK3, AR and AMACR mRNA levels, respectively
Fig. 3 AMACR mRNA expression levels in histologically benign and cancerous (carcinoma) samples from three prostate cross-sections obtained
from three patients with localized PCa who underwent RP. The 10/25/50/75/90th percentiles are marked in the figures. Open circles represent the
outlier values
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sections. More specifically, AMACR staining was posi-
tive in 100 % of areas that contained carcinoma in both
superior and inferior sides of cross-sections from pros-
tate B and C. However on the superior side of prostate
A, AMACR staining was positive in 96 % of the carcin-
oma areas while some Gleason 4 + 5 carcinoma foci were
found virtually AMACR negative (Fig. 4c-d). Strong
positive AMACR staining was constantly observed in
prostatic intraepithelial neoplasia (PIN) lesions (Fig. 4e-f).
While the great majority of normal prostatic glands
were AMACR negative, we occasionally observed
some weak AMACR staining in morphologically be-
nign glands especially adjacent to carcinoma lesions.
However, the staining in such glands was virtually sig-
nificantly weaker when compared to that seen in car-
cinoma and PIN lesion. These results suggest that
AMACR mRNA is globally expressed in cancerous
prostates while AMACR protein is most abundant in
carcinoma and PIN lesions.
Discussion
Each year a large number of the men undergo repeat bi-
opsy due to elevated PSA level. Repeat biopsy results
have demonstrated high rates of false negative results of
initial prostate biopsy (10 % to 30 %) [21, 22]. The
biopsy procedure is expensive and carries several risks
and discomfort for the patients. Therefore, finding reli-
able molecular markers that would enable early and
accurate diagnosis of PCa is of importance.
Numerous studies based on the measurement of
mRNA and/or protein expression have reported the up-
regulation of a variety of markers in PCa such as
AMACR and AR. Based on several previous immunohis-
tochemistry studies, AMACR is used as a routine tissue
Fig. 4 Immunohistochemical analysis of AMACR protein expression in different prostatic lesions. Hematoxylin-eosin (HE) and AMACR staining from
the same region of interest are shown. a, b Typical acinar Gleason 3 + 4 adenocarcinoma stains strongly for AMACR (open arrow) while the normal
glands are AMACR negative (filled arrow). c, d Gleason 4 + 5 adenocarcinoma shows focal positive staining for AMACR (open arrow) while some
of the poorly differentiated carcinoma glands (open arrowhead) and normal glands (filled arrow) are AMACR negative. e, f: High grade PIN lesion
shows positive AMACR staining (filled arrowhead) while morphologically normal glands show weak or no AMACR staining (filled arrow). Scale bar
200 μm (a-b), 100 μm (c-f)
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biomarker to support the diagnosis of prostate cancer
[4, 12, 23, 24] and especially useful for detection of
small carcinoma foci in needle biopsies when com-
bined with basal cell marker such as keratin 5/6 or
p63 [12]. Furthermore, AMACR immunocytochem-
istry and microscopic evaluation of cells captured
from post-DRE urine has been applied for detection
of PCa [25]. However, there are relatively few studies
on AMACR or AR mRNA expression levels in pros-
tate cancer tissue [26, 27]. Against this background,
we measured the mRNA expression levels of AMACR
and AR in 157 malignant and histologically benign
prostate tissues with qRT-PCR assays.
We observed an overexpression of both AMACR and
AR mRNA in not only cancerous, but also in histologi-
cally benign tissue from prostates with clinically signifi-
cant carcinomas when they were compared to prostates
without tumor or harboring only incidental lesions. Both
mRNAs were also positively associated with advanced
pathologic stage. The detected overexpression in cancer-
ous tissues was 682-fold for AMACR mRNA and 11.5-
fold for AR mRNA compared to prostates without any
evidence of cancer. However, no differences in gene
expression were seen when cancerous and histologically
benign tissues from PCa patients were compared, except
for AMACR/KLK3 mRNA ratio. This supports the find-
ing in a previous study by Laxman et al. that AMACR as
a single marker does not have sufficient sensitivity and
specificity and that it could provide better detection of
PCa only in a multiplex setting [28].
Finding abnormal AMACR levels in benign tissues
motivated us to examine the alteration in AMACR mRNA
levels and protein expression in a systematic way in cross-
sections of whole cancerous prostates. On the protein
level, expression of AMACR is sometimes detected in be-
nign biopsies from patients with PCa, as well as in normal
glands that were in closer proximity to a carcinoma foci
[5]. Similar results we obtained in the present study
(Fig. 4). The phenomenon of increased biomarker expres-
sion in histologically benign tissue in itself can be due to
cancer field effect [29, 30]. Field cancerization or field
effect which was suggested by Slaughter et al. in 1953 [31]
has an extended definition nowadays and it defines as any
molecular abnormalities in tissues that appear histologi-
cally benign [32]. We found that in contrast to the
carcinoma-free CP specimens where AMACR expression
was rare, AMACR mRNA was detectable in all benign,
carcinoma and PIN samples obtained from the three stud-
ied prostate cross-sections with highest levels in carcin-
oma samples. As expected, AMACR staining was detected
in the carcinoma areas, but not in all of them, and add-
itionally, it was seen in some of the benign and PIN areas.
As expected, AMACR staining was strongly positive in
the great majority (but not all) carcinoma and PIN lesions.
In additionally, we occasionally observed variable AMACR
positivity in morphologically benign glands either adjacent
to or separated from the cancerous foci showing that
AMACR expression is not specific for PCa. Accordingly,
measurement of the AMACR protein in urine samples by
ELISA has not been able to discriminate between BPH
and PCa better than serum PSA suggesting that AMACR
may also be expressed under reactive conditions such as
hyperplasia
In addition to the naturally occurring variable expression
in benign glands [5], the difference between mRNA and
protein level may be at least partly due to sensitivity limita-
tions and differences in antibodies and detection systems
[10, 13, 23]. Another possibility is the fact that the experi-
mental set-up used here is unable to specifically account
for the tissue shrinkage during fixation, which may affect
the accuracy in defining the exact sample areas that corres-
pond to the sample pieces in mRNA measurements and
thereby affect especially the data obtained from samples
adjacent to carcinoma foci. In this study we used samples
from men with Caucasian ethnicity, but previously lower
sensitivity and specificity of AMACR for the diagnosis of
PCa has been reported for example in Japanese patients
[33]. The involvement of AMACR in peroxisomal beta-
oxidation of branched-chain fatty acids and the differences
in diet habits between western and Japanese men could be
considered as one explanation but extra validation using
patient cohorts from different ethnic origins are needed to
fully understand the differences in AMACR expression in
the future. Nevertheless, the combined mRNA and protein
data from the cross-sections could suggest that qRT-PCR
assays are more sensitive than immunohistochemistry to
reveal potential carcinoma lesions, because in accordance
with our results for carcinoma samples in immunohisto-
chemical analysis, it has been reported that some small foci
of prostate cancers can be negative for AMACR staining
[34]. One limitation of this study was using fresh frozen
material while FFPE material is used in routine practice.
The positive aspect of using fresh frozen, rapidly processed
and stored in RNA stabilization reagent is that it clearly ap-
proaches the in-vivo situation. Using FFPE samples for
gene expression studies are challenging due to RNA deg-
radation and modification during the embedding and fix-
ation. Gene expression analysis of AMACR and AR in
FFPE samples using novel technologies such as nCounter
(NanoString® Technologies, USA) could be considered as
further validation in future.
Conclusion
Similar expression of AMACR transcripts in all of the
RP-Be and RP-PCa samples suggests that AMACR ex-
pression is increased also in the histologically benign
areas of cancerous prostates. This could potentially indi-
cate a global overexpression of AMACR as was detected
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in the preliminary yet systematic cross-section study
here. Hence, it could be deduced that patients with false
negative biopsies (i.e., lesion missed in the biopsies)
might benefit from an AMACR mRNA measurement
with a qRT-PCR assay when assessing their cancer risk.
Although this study was limited in the number of con-
trol tissue samples from PCa-free patients, but these
data poses interesting options for further studies. In the
future, this assay could also be applied to different sam-
ple matrices such as urine samples in order to move
towards developing a noninvasive assay.
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